Amneal Pharmaceuticals Inc (NYSE:AMRX) shares gapped up before the market opened on Wednesday . The stock had previously closed at $9.15, but opened at $9.13. Amneal Pharmaceuticals shares last traded at $8.57, with a volume of 13622 shares traded.

A number of brokerages recently issued reports on AMRX. Cantor Fitzgerald reissued a “buy” rating and issued a $35.00 price objective on shares of Amneal Pharmaceuticals in a research note on Thursday, February 28th. Svb Leerink cut shares of Amneal Pharmaceuticals from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $16.00 to $12.00 in a research note on Friday, March 8th. Raymond James raised shares of Amneal Pharmaceuticals from a “market perform” rating to a “strong-buy” rating and set a $13.00 price objective on the stock in a research note on Tuesday. They noted that the move was a valuation call. SunTrust Banks began coverage on shares of Amneal Pharmaceuticals in a research note on Tuesday, March 19th. They issued a “buy” rating and a $16.00 price objective on the stock. Finally, Leerink Swann cut shares of Amneal Pharmaceuticals to a “market perform” rating in a research note on Friday, March 8th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $19.60.

The company has a market cap of $2.56 billion, a PE ratio of 9.12, a P/E/G ratio of 0.50 and a beta of 1.31. The company has a current ratio of 2.11, a quick ratio of 1.37 and a debt-to-equity ratio of 3.44.

Amneal Pharmaceuticals (NYSE:AMRX) last announced its quarterly earnings data on Thursday, May 9th. The company reported $0.11 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.07). The firm had revenue of $446.00 million during the quarter, compared to the consensus estimate of $438.18 million. Amneal Pharmaceuticals had a negative net margin of 3.75% and a positive return on equity of 32.14%. Amneal Pharmaceuticals’s revenue for the quarter was up 4.9% compared to the same quarter last year. Equities analysts anticipate that Amneal Pharmaceuticals Inc will post 0.95 EPS for the current fiscal year.

In related news, SVP Pradeep Bhadauria bought 7,000 shares of the firm’s stock in a transaction on Wednesday, May 15th. The shares were purchased at an average price of $8.48 per share, with a total value of $59,360.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Peter R. Terreri sold 23,345 shares of the business’s stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $12.39, for a total transaction of $289,244.55. The disclosure for this sale can be found here. In the last ninety days, insiders have acquired 58,000 shares of company stock worth $590,790. Insiders own 26.34% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. grew its stake in shares of Amneal Pharmaceuticals by 2.1% during the fourth quarter. BlackRock Inc. now owns 6,053,727 shares of the company’s stock worth $81,909,000 after buying an additional 121,800 shares during the last quarter. TCW Group Inc. lifted its holdings in shares of Amneal Pharmaceuticals by 2.8% during the first quarter. TCW Group Inc. now owns 2,302,363 shares of the company’s stock worth $32,625,000 after purchasing an additional 63,423 shares during the period. Neuberger Berman Group LLC lifted its holdings in shares of Amneal Pharmaceuticals by 1.7% during the first quarter. Neuberger Berman Group LLC now owns 1,709,999 shares of the company’s stock worth $24,227,000 after purchasing an additional 28,747 shares during the period. Norges Bank acquired a new position in shares of Amneal Pharmaceuticals during the fourth quarter worth $18,243,000. Finally, Geode Capital Management LLC lifted its holdings in shares of Amneal Pharmaceuticals by 7.1% during the first quarter. Geode Capital Management LLC now owns 953,580 shares of the company’s stock worth $13,512,000 after purchasing an additional 63,600 shares during the period. 38.31% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This piece was originally reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The legal version of this piece can be accessed at https://theolympiareport.com/2019/05/22/amneal-pharmaceuticals-amrx-shares-gap-up-to-9-13.html.

About Amneal Pharmaceuticals (NYSE:AMRX)

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.

Featured Article: Fundamental Analysis and Individual Investors

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.